Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D V Spicer

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2001
Mammographic density changes during the menstrual cycleG Ursin, Y R Parisky, M C Pike, et al.
Cancer Research|January 15, 1988
Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokineticsD V Spicer, B Ardalan, J R Daniels, et al.
Contraception|May 1, 1993
Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancerD V Spicer, M C Pike, A Pike, et al.
Ernst Schering Foundation Symposium Proceedings|June 11, 2008
Estrogens, progestins, and risk of breast cancerM C Pike, A H Wu, D V Spicer, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancerD V Spicer, A Kelley, R Herman, et al.
Journal of the National Cancer Institute|January 17, 1996
Can mammographic densities predict effects of tamoxifen on the breast?G Ursin, M C Pike, D V Spicer, et al.
Cancer Investigation|January 1, 1995
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinomaM Turrill, D V Spicer, A S Kelley, et al.
Journal of the National Cancer Institute|March 16, 1994
Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer riskD V Spicer, G Ursin, Y R Parisky, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluationJ D Roberts, E A Poplin, M B Tombes, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 1998
The detection of changes in mammographic densitiesG Ursin, M A Astrahan, M Salane, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2001
Mammographic density changes during the menstrual cycleG Ursin, Y R Parisky, M C Pike, et al.
Cancer Research|January 15, 1988
Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokineticsD V Spicer, B Ardalan, J R Daniels, et al.
Contraception|May 1, 1993
Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancerD V Spicer, M C Pike, A Pike, et al.
Ernst Schering Foundation Symposium Proceedings|June 11, 2008
Estrogens, progestins, and risk of breast cancerM C Pike, A H Wu, D V Spicer, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancerD V Spicer, A Kelley, R Herman, et al.
Journal of the National Cancer Institute|January 17, 1996
Can mammographic densities predict effects of tamoxifen on the breast?G Ursin, M C Pike, D V Spicer, et al.
Cancer Investigation|January 1, 1995
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinomaM Turrill, D V Spicer, A S Kelley, et al.
Journal of the National Cancer Institute|March 16, 1994
Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer riskD V Spicer, G Ursin, Y R Parisky, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluationJ D Roberts, E A Poplin, M B Tombes, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 1998
The detection of changes in mammographic densitiesG Ursin, M A Astrahan, M Salane, et al.
Pageof 4